Title
Category
Credits
Event date
Cost
  • Muscular Dystrophy
  • Psychopharmacology
  • Patient/Physician Communication
  • Obsessive-Compulsive and Related Disorders
  • Violence/Aggression
  • Sleep
  • Side Effects
  • Delivery of Care
  • Cognition
  • Child and Adolescent Psychiatry
  • Depression
  • Attention-Deficit/Hyperactivity Disorder
  • Diagnostic Tools
  • Weight
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
This video reviews treatment guidelines for patients with DMD and emphasizes the importance of clinicians intervening early on behalf of individuals who develop behavioral-psychosocial comorbidities.
  • Cognition
  • Geriatric Psychiatry
  • Primary Care
  • Substance Use Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
When older patients present with cognitive decline, it is important to rule out any organic, mood-related, or substance-induced etiology, such as alcohol use disorder.
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Diagnostic Tools
  • Patient/Physician Communication
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
In this webcast about early-stage Alzheimer disease, Drs Burke and Apostolova highlight important conversations to have with patients and their care partners on topics such as diet, exercise, driving, and plans for the later stage of illness.
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
What are the steps for diagnosing Alzheimer disease? Are you familiar with diagnostic criteria and assessment tools? In this webcast, walk through the process with an expert.
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Geriatric Psychiatry
  • Neurology
  • Primary Care
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Learn from experts in neurology, psychiatry, neuropsychology, and primary care about working with patients and care partners to create management plans for Alzheimer’s disease that ensure safety, optimize patient autonomy, and minimize agitation and conflict.
  • Adherence
  • Antipsychotics
  • Cognition
  • Neuropsychiatric Disorders
  • Patient/Physician Communication
  • Psychopharmacology
  • Psychotic Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Sexual Dysfunction
  • Side Effects
  • Veterans and Military Issues
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Side effects from medication have the greatest impact on adherence for patients with Schizophrenia. They lower quality of life, daily functioning, and satisfaction.
  • Adherence
  • Antipsychotics
  • Cognition
  • Neuropsychiatric Disorders
  • Patient/Physician Communication
  • Psychopharmacology
  • Psychotic Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Sexual Dysfunction
  • Side Effects
  • Veterans and Military Issues
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Schizophrenia affects 1% of the world’s population largely during a patient’s most productive years. Multiple treatments are available, however many gaps to recovery exist. Learn from experts diagnostic criteria for and defining recovery in schizophrenia.
  • Adherence
  • Antipsychotics
  • Cognition
  • Neuropsychiatric Disorders
  • Patient/Physician Communication
  • Psychopharmacology
  • Psychotic Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Sexual Dysfunction
  • Side Effects
  • Veterans and Military Issues
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Negative symptoms contribute to poor functional outcomes in schizophrenia. Evaluating different symptom domains and understanding the disorder’s reward circuitry can help with intervention and patients’ leading more fulfilling lives.
  • Adherence
  • Antipsychotics
  • Cognition
  • Neuropsychiatric Disorders
  • Patient/Physician Communication
  • Psychopharmacology
  • Psychotic Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Sexual Dysfunction
  • Side Effects
  • Veterans and Military Issues
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Balancing symptoms and side effects is difficult when treating patients with schizophrenia. New approaches to treatment and new therapies in the pipeline offer hope for this difficult-to-treat mental health disorder.
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Diagnostic Tools
  • Education
  • Functional Impairment
  • Geriatric Psychiatry
  • Neuroimaging
  • Neurology
  • Patient/Physician Communication
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Drs Anderson and Malone cover the types of dementia and their indicators, ways to approach care for mild cognitive impairment (MCI) and mild dementia, and treatment options available or in the pipeline for disease intervention. Early diagnosis and intervention of MCI and mild dementia can slow disease progression and optimize outcomes for both patients and caregivers.

Pages